Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- ribonucleic acid
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 372110
Irofulven has two primary anti-tumor mechanisms of action first, it produces bulky single strand DNA adducts that are only repairable by the transcription coupled nucleotide excision repair (TC-NER) pathway; and second, it stalls RNA polymerase II leading to transcription and cell cycle arrest and apoptosis.
Irofulven is a well-studied small molecule that causes bulky single strand DNA adducts that cause DNA damage in cancer cells, which can only be repaired by the transcription coupled nucleotide excision repair (TC-NER) pathway. This DNA modification stalls RNA polymerase II leading to transcription and cell cycle arrest and apoptosis in certain types of cancer cells.
IPSCIO Record ID: 371878
Stenoparib, a novel inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase (PARP), and IXEMPRAÂ® (ixabepilone), a selective microtubule inhibitor, which also has, in clinically relevant doses, a unique inhibitory action against Tankyrases, another important group of DNA damage repair enzymes. DNA damage repair mechanisms are crucial to mammalian cell survival and replication, and so inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancer. Tankyrases are enzymes involved in the stabilization and maintenance of telomeres (the ends of chromosomal DNA) during cell replication, and so disruption of Tankyrases is thought to provide an additional mechanism of impeding cancer cell growth.
Stenoparib is currently being evaluated for the treatment of advanced ovarian cancer in a DRPÂ®-guided Phase 2 clinical trial.
The expansion of the field-of-use rights will support Allarity in its advancement of Stenoparib as a potential anti-viral therapy for COVID-19.
IPSCIO Record ID: 369284
Licensed Patent means (a) U.S. Provisional Patent Application Nos. 62/041,368, 61/124,359. 61/124,328, 61/114,153 International Patent Application No. PCT/US2009/02392 U.S. Patent Application No. 12/988,299, Canadian Patent Application No. 2,721,506 and European Patent Application No. 09733012.0 and the inventions disclosed and claimed therein
Technology related to the development of a companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with the Companyâ€™s lead product, galeterone, which is in development for the treatment of AR-V7 positive metastatic CRPC.
Galeterone is a highly selective, multi-targeted, oral small molecule drug candidate that has advantages over existing prostate cancer therapies. Galeterone acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that drives prostate cancer growth. The pathway is ordinarily activated by the binding of male hormones, or androgens, such as testosterone and the more potent androgen dihydrotestosterone, or DHT, to the ligand binding domain of androgen receptors in prostate cancer cells. Galeterone disrupts the activation of the pathway through multiple mechanisms of action.
Field of Use companion diagnostic for Galeterone (excluding commercial sale as research reagent).
IPSCIO Record ID: 26619
O6-Benzylguanine (O6-BG) is a chemosensitizer that is designed to overcome resistance to a significant class of commonly used chemotherapeutic agents known as O6-alkylating agents. In preclinical animal studies, treatment with O6-BG increased the anti-tumor activity of these agents in brain, colon, and prostate cancers, as well as in melanoma. A Phase II development program began in 1999. O6-BG, a series of related compounds and a gene therapy that the Company believes will enhance the effectiveness of a class of currently used chemotherapeutic agents known as O6-alkylating agents. O6-BG and related compounds are small molecules for intravenous administration in the treatment of cancer. The Company believes O6-BG to be capable of destroying the resistance of cancer cells to a class of chemotherapeutic agents, O6-alkylating agents. The Company believes that the effectiveness of alkylating chemotherapeutic agents against various tumors such as brain, prostate, colon cancers, melanoma and lymphoma is limited due to the ability of tumor cells to repair the DNA damage caused by the O6-alkylating agents, because the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT), protects tumor cells by repairing the tumor cell DNA.
The Company believes that O6-BG inactivates the AGT protein in a variety of cancers thereby overcoming resistance to theO6-alkylating agents.
IPSCIO Record ID: 299237
— a non-exclusive license under the Patent Rights, to make, have made, use, and/or sell Licensed Products for human and non-human applications;
— the right under the Patent Rights to grant to an Affiliate a sublicense; and,
— the right under the Patent Rights to grant to Product Development Partner(s) a single sublicense for each specific application of Licensed Product.
The Designated Product shall mean a protein or other product produced through use of the T7 technology.
SGN-10 is a single-chain immunotoxin that binds to cancer cells and kills them by delivering a protein toxin inside the cell. SGN-10 is composed of the receptor binding portion of the BR96 monoclonal antibody and a truncated portion of a protein toxin called Pseudomonas exotoxin A. SGN-10 is currently in two phase I clinical trials.
The term 'Patent Rights' shall mean
1. United States Patent No. 4,952,496 entitled 'Cloning and Expression of the Gene for Bacteriophage T7 RNA Polymerase', and any reissue thereof;
2. U.S. Patent No. 5,693,489 entitled 'Cloning and Expression of the Gene for Bacteriophage T7 RNA Polymerase', and any reissue thereof;